keyword
MENU ▼
Read by QxMD icon Read
search

Glucagon-like peptide

keyword
https://www.readbyqxmd.com/read/29457300/glucagon-like-peptide-2-decreases-osteoclasts-by-stimulating-apoptosis-dependent-on-nitric-oxide-synthase
#1
Yi Lu, Dongdong Lu, Yu Hu
OBJECTIVES: Glucagon-like peptide 2 (GLP2) is involved in the regulation of energy absorption and metabolism. Despite the importance of the GLP2 signalling mechanisms on osteoclast, little has been studied on how GLP2 works during osteoclastogenesis. MATERIALS AND METHODS: RAW264.7 cells were infected with rLV-Green-GLP2. The induction of osteoclasts was performed by RANKL. TRAP were detected by RT-PCR, Western blotting and staining. Total nitric oxide and total NOS activity were measured...
February 19, 2018: Cell Proliferation
https://www.readbyqxmd.com/read/29454696/the-effect-of-tube-versus-bottle-feeding-colostrum-on-immunoglobulin-g-absorption-abomasal-emptying-and-plasma-hormone-concentrations-in-newborn-calves
#2
M Desjardins-Morrissette, J K van Niekerk, D Haines, T Sugino, M Oba, M A Steele
The objective of this study was to determine if feeding colostrum to newborn calves through an esophageal tube, compared with a nipple bottle, would delay abomasal emptying, which would in turn decrease passive transfer of IgG and plasma glucose, insulin, and glucagon-like peptide (GLP) 1 and GLP-2 concentrations. Twenty newborn Holstein bull calves were fed 3 L of colostrum replacer (200 g of IgG) through either an esophageal tube or nipple bottle at 2 h after birth followed by feeding pooled whole milk every 12 h after birth...
February 14, 2018: Journal of Dairy Science
https://www.readbyqxmd.com/read/29454620/extracellular-loops-2-and-3-of-the-calcitonin-receptor-selectively-modify-agonist-binding-and-efficacy
#3
Emma Dal Maso, Yue Zhu, Vi Pham, Christopher A Reynolds, Giuseppe Deganutti, Caroline A Hick, Dehua Yang, Arthur Christopoulos, Debbie L Hay, Ming-Wei Wang, Patrick M Sexton, Sebastian G B Furness, Denise Wootten
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage. Recent active structures of the calcitonin (CT) and glucagon-like peptide-1 (GLP-1) receptors reveal distinct engagement of peptides with extracellular loops (ECLs) 2 and 3, and mutagenesis of the GLP-1R has implicated these loops in dynamics of receptor activation. In the current study, we have mutated ECLs 2 and 3 of the human CT receptor (CTR), to interrogate receptor expression, peptide affinity and efficacy...
February 15, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29453982/glucagon-like-peptide-1-contributes-to-increases-abca1-expression-by-downregulating-mir-758-to-regulate-cholesterol-homeostasis
#4
Yue Yao, Qiang Li, Ping Gao, Wei Wang, Lili Chen, Jinchao Zhang, Yi Xu
Abnormal regulation of lipid metabolism is associated with type 2 diabetes mellitus (T2DM). GLP-1 as a new treatment for T2DM, has unique effects in modulating cholesterol homeostasis. However, the mechanism of this effect is largely missing. The aim of this study was to determine the effects of GLP-1 on cholesterol-induced lipotoxicity in hepatocytes and examine the underlying mechanisms. The cell viability was determined, and caspase-3 was used to detect the effects of GLP-1 on cholesterol-induced apoptosis...
February 14, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29453463/impact-of-gastric-emptying-and-small-intestinal-transit-on-blood-glucose-intestinal-hormones-glucose-absorption-in-the-morbidly-obese
#5
Nam Q Nguyen, Tamara L Debreceni, Jenna E Burgess, Max Bellon, Judith Wishart, Scott Standfield, Charles-Henri Malbert, Michael Horowitz
This study evaluated gastric emptying (GE) and small intestinal (SI) transit in people with morbid obesity and their relationships to glycaemia, incretin hormones, and glucose absorption METHODS: GE and caecal arrival time (CAT) of a mixed meal were assessed in 22 morbidly obese (50.2 ± 2.5 years; 13 F:9 M; BMI: 48.6 ± 1.8 kg/m2 ) and 10 lean (38.6 ± 8.4 years; 5 F:5 M; BMI: 23.9 ± 0.7 kg/m2 ) subjects, using scintigraphy. Blood glucose, plasma 3-O-methylglucose, insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were measured...
January 30, 2018: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/29451201/tackling-dipeptidyl-peptidase-iv-in-neurological-disorders
#6
REVIEW
Ghaith Al-Badri, Gian Marco Leggio, Giuseppe Musumeci, Rubina Marzagalli, Filippo Drago, Alessandro Castorina
Dipeptidyl peptidase IV (DPP-IV) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (GLP-1), pituitary adenylate cyclase-activating polypeptide (PACAP) and glucose-dependent insulinotropic peptide (GIP), three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal. Owing to the relationship between DPP-IV and these peptides, inhibition of DPP-IV enzyme activity is considered as an attractive treatment option for diabetic patients. Nonetheless, increasing studies support the idea that DPP-IV might also be involved in the development of neurological disorders with a neuroinflammatory component, potentially through its non-incretin activities on immune cells...
January 2018: Neural Regeneration Research
https://www.readbyqxmd.com/read/29450114/flavonoid-rich-extract-of-chromolaena-odorata-modulate-circulating-glp-1-in-wistar-rats-computational-evaluation-of-tgr5-involvement
#7
Olaposi Idowu Omotuyi, Oyekanmi Nash, Olumide Kayode Inyang, Joyce Ogidigo, Ojochenemi Enejoh, Okiemute Okpalefe, Tsuyoshi Hamada
Chromolaena odorata is a major bio-resource in folkloric treatment of diabetes. In the present study, its anti-diabetic component and underlying mechanism were investigated. A library containing 140 phytocompounds previously characterized from C. odorata was generated and docked (Autodock Vina) into homology models of dipeptidyl peptidase (DPP)-4, Takeda-G-protein-receptor-5 (TGR5), glucagon-like peptide 1 (GLP1) receptor, renal sodium dependent glucose transporter (SGLUT)-1/2 and nucleotide-binding oligomerization domain (NOD) proteins 1&2...
February 2018: 3 Biotech
https://www.readbyqxmd.com/read/29449951/glucagon-like-peptide-1-receptor-agonists-are-not-associated-with-retinal-adverse-events-in-the-fda-adverse-event-reporting-system
#8
Gian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro
Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes. In large trials, the GLP-1RAs liraglutide and semaglutide improved cardiovascular outcomes, but semaglutide was associated with an increased risk of retinopathy progression. We herein evaluated the association between GLP-1RA and retinal adverse events (AE) in the Food and Drug Administration Adverse Event Reporting System (FAERS). Research design and methods: We mined the FAERS between 2004q1 and 2017q1 (for a total of 9 217 555 AE reports) to analyze disproportionality and evaluate the association between GLP-1RAs and AEs involving the retina...
2018: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/29445896/glp-1-receptor-agonists-and-cardiovascular-disease-a-meta-analysis-of-recent-cardiac-outcome-trials
#9
Xiaoming Jia, Mahboob Alam, Yumei Ye, Mandeep Bajaj, Yochai Birnbaum
PURPOSE: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. METHODS: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. RESULTS: A total of 33,457 patients were included in the meta-analysis...
February 14, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29444223/glp-1-receptor-expression-within-the-human-heart
#10
Laurie L Baggio, Bernardo Yusta, Erin E Mulvihill, Xiemin Cao, Catherine J Streutker, Jagdish Butany, Thomas P Cappola, Kenneth B Margulies, Daniel J Drucker
Glucagon-like peptide-1 receptor (GLP-1R) agonists, used to treat type 2 diabetes and obesity, reduce rates of myocardial infarction and cardiovascular death. The GLP-1R has been localized to the human sinoatrial node; however, its expression in ventricular tissue remains uncertain. Here we studied GLP-1R expression in the human heart using GLP-1R-directed antisera, quantitative PCR, reverse transcription PCR to detect full length mRNA transcripts, and in situ hybridization. GLP1R mRNA transcripts, encompassing the entire open reading frame, were detected in all four cardiac chambers from 15 hearts at levels approximating those detected in human pancreas...
February 12, 2018: Endocrinology
https://www.readbyqxmd.com/read/29440961/acute-pancreatitis-during-glp-1-receptor-agonist-treatment-a-case-report
#11
Bogdan Augustin Chis, Daniela Fodor
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are the newest treatment for diabetes mellitus (DM). These drugs can down-regulate fasting glucose more than oral drugs and lead to more constant glucose levels compared to regular insulin. Acute pancreatitis is a serious condition that may have a fatal outcome. It has been shown that long term and high doses of GLP-1RA can cause pancreatic changes in animals, but no connection has been proven in humans. We present the case of a 67 years old man with DM treated with oral drugs for 10 years until 3 months before, when GLP-1RA was added...
2018: Clujul Medical (1957)
https://www.readbyqxmd.com/read/29439603/semaglutide-in-type-2-diabetes-is-it-the-best-glucagon-like-peptide-1-receptor-agonist-glp-1r-agonist
#12
Sheila A Doggrell
Glucagon-like peptide-1 (GLP-1) is produced by the gut, and in a glucose-dependent manner stimulates insulin secretion while inhibiting glucagon secretion, reduces appetite and energy intake, and delays gastric emptying. The GLP-1R agonist semaglutide has recently been registered for use in the treatment of type 2 diabetes. Area covered: This review is of semaglutide in type 2 diabetes, and considers which properties of this GLP-1R agonist, may be responsible for its clinical outcome benefits in this condition...
February 13, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29438631/plasma-endocannabinoid-levels-in-lean-overweight-and-obese-humans-relationships-with-intestinal-permeability-markers-inflammation-and-incretin-secretion
#13
Tanya J Little, Nada Cvijanovic, Nicholas V DiPatrizio, Donovan A Argueta, Christopher K Rayner, Christine Feinle-Bisset, Richard L Young
INTRODUCTION/AIMS: Intestinal production of endocannabinoid and oleoylethanolamide (OEA) is impaired in high-fat diet/obese rodents, leading to reduced satiety. Such diets also alter the intestinal microbiome in association with enhanced intestinal permeability and inflammation, however little is known of these effects in humans. This study aimed to: (i) evaluate effects of lipid on plasma anandamide (AEA), 2-arachidonyl-sn-glycerol (2-AG) and OEA in humans, and (ii) examine relationships with intestinal permeability, inflammation markers and incretin hormone secretion...
February 13, 2018: American Journal of Physiology. Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29435980/the-diabetes-drug-liraglutide-reverses-cognitive-impairment-in-mice-and-attenuates-insulin-receptor-and-synaptic-pathology-in-a-non-human-primate-model-of-alzheimer-s-disease
#14
Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital, Suelen A Marques, Ana M B Martinez, Matthias Gralle, Christian Holscher, William L Klein, Jean-Christophe Houzel, Sergio T Ferreira, Douglas P Munoz, Fernanda G De Felice
Alzheimer's disease (AD) is a devastating neurological disorder that still lacks an effective treatment, and this has stimulated an intense pursuit of disease-modifying therapeutics. Given the increasingly recognized link between AD and defective brain insulin signaling, we investigated the actions of liraglutide, a glucagon-like peptide-1 (GLP-1) analog marketed for treatment of type 2 diabetes, in experimental models of AD. Insulin receptor pathology is an important feature of AD brains that impairs the neuroprotective actions of central insulin signaling...
February 12, 2018: Journal of Pathology
https://www.readbyqxmd.com/read/29434185/glucagon-like-peptide-1-receptor-regulates-endoplasmic-reticulum-stress-induced-apoptosis-and-the-associated-inflammatory-response-in-chondrocytes-and-the-progression-of-osteoarthritis-in-rat
#15
Jian Chen, Jun-Jun Xie, Ke-Si Shi, Yun-Tao Gu, Cong-Cong Wu, Jun Xuan, Yue Ren, Long Chen, Yao-Sen Wu, Xiao-Lei Zhang, Jian Xiao, De-Zhong Wang, Xiang-Yang Wang
Treatments for osteoarthritis (OA) are designed to restore chondrocyte function and inhibit cell apoptosis. Previous studies have shown that activation of the glucagon-like peptide-1 receptor (GLP-1R) leads to anti-inflammatory and anti-apoptotic effects. However, the role of GLP-1R in the pathological process of OA is unclear. In present work, we aimed to demonstrate the potential effect of GLP-1R on chondrocytes and elucidate its underlying mechanisms. We found that activation of GLP-1R with liraglutide could protect chondrocytes against endoplasmic reticulum stress and apoptosis induced by interleukin (IL)-1β or triglycerides (TGs)...
February 12, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29433086/potential-roles-for-glucagon-like-peptide-1-7-36-amide-and-cholecystokinin-in-anorectic-response-to-the-trichothecene-mycotoxin-t-2-toxin
#16
Wenda Wu, Kun Sheng, Xinglian Xu, Haibin Zhang, Guanghong Zhou
Anorexia is a hallmark of animal and human exposed to T-2 toxin, a most poisonous trichothecene mycotoxins contaminating various cereal grains including wheat, corn and barley. Although this adverse effect has been well characterized in several animal species, the underlying mechanisms are unclear. The goal for this study was to elucidate the roles of two gut satiety hormones, glucagon-like peptide-17-36amide (GLP-1) and cholecystokinin (CCK) in T-2 toxin-evoked anorectic response using a mouse anorexia bioassay...
February 9, 2018: Ecotoxicology and Environmental Safety
https://www.readbyqxmd.com/read/29432586/effects-of-different-starch-source-of-starter-on-small-intestinal-growth-and-endogenous-glp-2-secretion-in-pre-weaned-lambs
#17
Daming Sun, Hongwei Li, Shengyong Mao, Weiyun Zhu, Junhua Liu
The objective of this study was to investigate the effects of different source of starch in starter feed on small intestinal growth and endogenous glucagon-like peptide 2 (GLP-2) secretion in pre-weaned lambs. Twenty-four 10-day-old lambs were divided into three groups that were treated with different iso-starch diets containing purified cassava starch (CS, n = 8), maize starch (MS, n = 8) and pea starch (PS, n = 8). At 56 days old, there was no significant difference in final body weight (BW) of lambs among the three groups...
February 8, 2018: Journal of Animal Science
https://www.readbyqxmd.com/read/29432213/regulation-of-intestinal-lipid-and-lipoprotein-metabolism-by-the-proglucagon-derived-peptides-glucagon-like-peptide-1-and-glucagon-like-peptide-2
#18
Erin E Mulvihill
PURPOSE OF REVIEW: The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 (GLP-1) and glucagon like peptide 2 (GLP-2) on intestinal lipoprotein secretion. RECENT FINDINGS: Several recent studies have elucidated mechanisms underlying the paradoxical effects of GLP-1 and GLP-2 on intestinal production of triglyceride-rich lipoproteins (TRLs)...
February 9, 2018: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/29431535/differences-in-the-postprandial-release-of-appetite-related-hormones-between-active-and-inactive-men
#19
Linn Bøhler, Sílvia Ribeiro Coutinho, Jens F Rehfeld, Linda Morgan, Catia Martins
Active, as opposed to inactive, individuals are able to adjust their energy intake after preloads of different energy content. The mechanisms responsible for this remain unknown. This study examined differences in plasma concentration of appetite-related hormones in response to breakfasts of different energy content, between active and inactive men. 16 healthy non-obese (BMI 18.5-27 kg/m 2 ) adult males (9 active, 7 inactive), participated in the study. Participants were given a high- (HE, 570 kcal) or a low-energy (LE, 205 kcal) breakfast in random order...
February 12, 2018: International Journal of Sport Nutrition and Exercise Metabolism
https://www.readbyqxmd.com/read/29430842/glucagon-like-peptide-1-glp-1-based-therapeutics-current-status-and-future-opportunities-beyond-type-2-diabetes
#20
Jia Ying Cheang, Peter Michael Moyle
Glucagon-like peptide-1 (GLP-1) is secreted by intestinal L-cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose-dependent insulin secretion. Further, GLP-1 is also associated with protective effects on pancreatic β-cells and the cardiovascular system, reduced appetite, and weight loss, making GLP-1 derivatives an exciting treatment for type 2 diabetes and obesity. Despite these benefits, wild-type GLP-1 exhibits a short circulation time, due to its poor metabolic stability and rapid renal clearance, and needs to be administered by injection, making it a poor therapeutic agent...
February 11, 2018: ChemMedChem
keyword
keyword
67329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"